These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 19342958

  • 1. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM, Ryan CJ.
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [Abstract] [Full Text] [Related]

  • 2. Novel concepts in androgen receptor blockade.
    Hsieh AC, Ryan CJ.
    Cancer J; 2008 May; 14(1):11-4. PubMed ID: 18303477
    [Abstract] [Full Text] [Related]

  • 3. The case for secondary hormonal therapies in the chemotherapy age.
    Small EJ, Ryan CJ.
    J Urol; 2006 Dec; 176(6 Pt 2):S66-71. PubMed ID: 17084172
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J.
    Eur Urol; 1997 Dec; 32 Suppl 3():78-80. PubMed ID: 9267790
    [Abstract] [Full Text] [Related]

  • 6. Secondary hormonal manipulations in prostate cancer.
    Ryan CJ.
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):925-34. PubMed ID: 16861123
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Recent progress in hormonal therapy for advanced prostate cancer.
    Daskivich TJ, Oh WK.
    Curr Opin Urol; 2006 May; 16(3):173-8. PubMed ID: 16679855
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Molecular determinants of resistance to antiandrogen therapy.
    Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL.
    Nat Med; 2004 Jan; 10(1):33-9. PubMed ID: 14702632
    [Abstract] [Full Text] [Related]

  • 14. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H, Garcia JA.
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [Abstract] [Full Text] [Related]

  • 15. Secondary hormonal manipulations in the management of advanced prostate cancer.
    Chaudhary UB, Rashid MH, Onitilo AA, Bissada NK.
    Can J Urol; 2005 Jun; 12(3):2666-76. PubMed ID: 16011813
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H, Messing EM, Chang C.
    Prostate; 2004 Dec 01; 61(4):332-53. PubMed ID: 15389811
    [Abstract] [Full Text] [Related]

  • 19. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.
    Molina A, Belldegrun A.
    J Urol; 2011 Mar 01; 185(3):787-94. PubMed ID: 21239012
    [Abstract] [Full Text] [Related]

  • 20. Overcoming castration resistance in prostate cancer.
    Tsao CK, Small AC, Galsky MD, Oh WK.
    Curr Opin Urol; 2012 May 01; 22(3):167-74. PubMed ID: 22472508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.